Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
<h3>Introduction:</h3><p dir="ltr">Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hen...
Saved in:
Similar Items
-
The efficacy of colchicine in the management of coronavirus disease 2019
by: Mohamed Nabil Elshafei (9960500)
Published: (2020) -
The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials
by: Ayesha, Younas
Published: (2024) -
Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
by: Mohamad Y. Khatib (11659459)
Published: (2020) -
Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses
by: Mohammed I., Danjuma
Published: (2023) -
The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials
by: Ayesha Younas (7114868)
Published: (2025)